The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
cdercder
Nole
Wells
DW
dde
无极微光
Kao
小乔
挖掘机
XX
皓月搞科研
aaaa
冷木子
秋风
Criminology34
Dean
aajhajkahna
共产主义战士
一只鱼
学术文献互助
皖公网安备34019202002308
